Stratophase Announces a Joint Collaboration Agreement to Develop Advanced Multi-Component Dynamic Feeding Control for Upstream Bioprocesses Used in Biopharma Manufacturing
Stratophase has announced that it has entered into a joint collaboration agreement with Merck, a leading science and technology company
16 Feb 2017
The collaboration will see the application of Stratophase’s Ranger® technology to Merck’s cell culture manufacturing platforms and the development of dynamic control strategies that enable complex feeding regimes to be optimized and controlled in real-time. Enhancement of the existing Ranger system’s capabilities to enable control of cell culture processes with complex feeding requirements is aligned with the biopharmaceutical industry’s increasing need for high performance and robust processes that can be optimized and implemented within minimum timelines.
“We are proud to be collaborating with Merck to further the impact that Ranger is having on revolutionizing upstream process development and control for the manufacture of biologics,” said Simon Saxby, CEO of Stratophase. “Merck’s considerable expertise in media design and cell culture techniques, combined with Stratophase’s unique process development knowledge leveraged by Ranger®, gives the ideal platform for developing, testing and implementing new control strategies”.
“Biologics are becoming increasingly complex due to diversifying pipelines, leading to challenging manufacturing requirements,” said Hervé Broly, Vice President, Biotech Process sciences at the biopharma business of Merck. “The collaboration with Stratophase offers a route to dynamic process monitoring and control and the ability to adapt the process in real-time for specific on-demand requirements, thereby ensuring high process performance and robustness at scale.”